Literature DB >> 12615170

Leber's congenital amaurosis: an update.

Elisa Fazzi1, Sabrina Giovanna Signorini, Barbara Scelsa, Stefania Maria Bova, Giovanni Lanzi.   

Abstract

Leber's congenital amaurosis (LCA) is a clinically and genetically heterogeneous disorder characterized by severe loss of vision at birth. It accounts for 10-18% of cases of congenital blindness. Some patients exhibit only blindness of retinal origin whereas others show evidence of a multi-systemic involvement. We review the literature relating to this severe disorder, highlighting unresolved questions, in particular the nature of the association of LCA with mental retardation and with systemic findings and syndromic pictures. In recent years, genetic advances in the diagnosis of LCA have opened up new horizons, also from a therapeutic point of view. A better understanding of this pathology would be valuable for paediatric neurologists.

Entities:  

Mesh:

Year:  2003        PMID: 12615170     DOI: 10.1016/s1090-3798(02)00135-6

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  16 in total

Review 1.  Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms.

Authors:  Paulo A Ferreira
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

2.  Phenotype of three consanguineous Tunisian families with early-onset retinal degeneration caused by an R91W homozygous mutation in the RPE65 gene.

Authors:  Leila El Matri; Aude Ambresin; Daniel F Schorderet; Aki Kawasaki; Mathias W Seeliger; Andreas Wenzel; Yvan Arsenijevic; François-Xavier Borruat; Francis L Munier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02-28       Impact factor: 3.117

Review 3.  Review and update on the molecular basis of Leber congenital amaurosis.

Authors:  Oscar Francisco Chacon-Camacho; Juan Carlos Zenteno
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

4.  Correlation of ultra-widefield fundus autofluorescence patterns with the underlying genotype in retinal dystrophies and retinitis pigmentosa.

Authors:  George Trichonas; Elias I Traboulsi; Justis P Ehlers
Journal:  Ophthalmic Genet       Date:  2016-11-23       Impact factor: 1.803

5.  Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.

Authors:  Xia Li; Wensheng Li; Xufeng Dai; Fansheng Kong; Qinxiang Zheng; Xiangtian Zhou; Fan Lü; Bo Chang; Bärbel Rohrer; William W Hauswirth; Jia Qu; Ji-jing Pang
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

6.  Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice.

Authors:  Tadao Maeda; Akiko Maeda; Gemma Casadesus; Krzysztof Palczewski; Philippe Margaron
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

7.  Ultra-widefield fundus autofluorescence patterns in retinitis pigmentosa and other retinal dystrophies.

Authors:  George Trichonas; Elias I Traboulsi; Justis P Ehlers
Journal:  Ophthalmic Genet       Date:  2016-04-06       Impact factor: 1.803

8.  Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patients.

Authors:  Paolo Melillo; Leandro Pecchia; Francesco Testa; Settimio Rossi; Jean Bennett; Francesca Simonelli
Journal:  Biomed Eng Online       Date:  2012-07-19       Impact factor: 2.819

9.  Leber congenital amaurosis associated with Chiari I malformation: Two cases and a review of the literature.

Authors:  Anthony L Petraglia; Harris U Chengazi; Mina M Chung; Howard J Silberstein
Journal:  Surg Neurol Int       Date:  2012-01-21

10.  Early noninvasive prenatal detection of a fetal CRB1 mutation causing Leber congenital amaurosis.

Authors:  Ana Bustamante-Aragones; Elena Vallespin; Marta Rodriguez de Alba; Maria Jose Trujillo-Tiebas; Cristina Gonzalez-Gonzalez; Dan Diego-Alvarez; Rosa Riveiro-Alvarez; Isabel Lorda-Sanchez; Carmen Ayuso; Carmen Ramos
Journal:  Mol Vis       Date:  2008-08-04       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.